[21B7-21B7];[21B8-21B8];
A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
21B7;21B8
Breakpoint based on release 3 sequence coordinate from Thibault et al., 2004, Supplementary Table 2 (FBrf0174227) or 3 (FBrf0174228), converted to release 5 coordinate.
Breakpoint from FlyBase's release 5 sequence location of progenitor insertion.
The presence of P+PBac{XP5.WH5}BSC454 was verified using the PCR methods and primers described in FBrf0175003.
Exelixis, Inc. determined the insertion site of P{XP}d10144 to be Release 3 genomic coordinate 307085 on chromosome arm 2L. This corresponds to 21B8 on the Release 3 and Release 5 genome map. The predicted position of PBac{WH}CG3645f02260 on the Release 5 map is 21B7. Consequently, the cytological breakpoints of Df(2L)BSC454 are predicted to be 21B7;21B8.